戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ell lines for in vitro growth sensitivity to eribulin.
2 lish the all-carbon macrocyclic framework of eribulin.
3 s, pegylated liposomal doxorubicin, CAPE, or Eribulin.
4 approval include pazopanib, trabectedin, and eribulin.
5  mg (day 1), and apatinib 250 mg daily, plus eribulin 1.4 mg/m(2) (day 1 and 8) on a 21-day cycle unt
6 bine 1,000 mg/m(2) intravenously followed by eribulin 1.4 mg/m(2), both on days 1 and 8, repeated in
7 ts were more common in patients who received eribulin (152 [67%]) than in those who received dacarbaz
8  randomly allocated to treatment groups (508 eribulin, 254 TPC).
9 d the microtubule targeting anti-cancer drug Eribulin [5-7] to explore the consequences of stalled pr
10 g post hoc analysis examined the efficacy of eribulin according to the location of metastatic sites a
11  and washout/retention studies show that [3H]eribulin accumulates to lower intracellular levels than
12     In the per-protocol population (n = 87), eribulin achieved an independently reviewed objective re
13                                              Eribulin also binds microtubules with a maximum stoichio
14 in the absence of any drugs, we propose that Eribulin amplifies a natural pathway toward catastrophe
15      Objective response rates were 11.0% for eribulin and 11.5% for capecitabine.
16 ed in 224 (99%) of 226 patients who received eribulin and 218 (97%) of 224 who received dacarbazine.
17 nd neutropenia (260 [52%] patients receiving eribulin and 73 [30%] of those on TPC at all grades).
18 nia or fatigue (270 [54%] of 503 patients on eribulin and 98 [40%] of 247 patients on TPC at all grad
19 d synthetic route for the total syntheses of eribulin and a macrolactam analog of halichondrin B is d
20                         Median PFS times for eribulin and capecitabine were 4.1 and 4.2 months, respe
21      Bcl-2 phosphorylation patterns parallel eribulin and ER-076349 mitotic block reversibility patte
22 iral formation is strongly inhibited by both eribulin and ER-076349.
23 53 function regulates anticancer activity of eribulin and the potential utility of TP53 null phenotyp
24 y of mitochondria in neuronal cells, whereas eribulin and vincristine inhibited transport only at sig
25 ng the lengths of microtubules and the drugs eribulin and vincristine that bind at microtubule ends,
26 whereas the microtubule-destabilizing drugs, eribulin and vincristine, which bind preferentially to m
27 ents (5-fluoruracil, carboplatin, cisplatin, eribulin, and paclitaxel), based on their continued viab
28 cassette B1, defined resistance mechanism to eribulin, and paclitaxel.
29  a permuted block scheme by region, previous eribulin, and receptor status.
30                                              Eribulin appeared efficacious in patients with locally a
31 eir targets, microtubule inhibitors, such as eribulin, are deployed in an unselected manner.
32 improvement in overall survival (OS) for the eribulin arm, with a manageable toxicity profile.
33  lines exhibiting the highest sensitivity to eribulin bear TP53 null phenotypes, supporting a rationa
34 inblastine induced additional lower-affinity eribulin binding sites, most likely at splayed microtubu
35          Using [(3)H]eribulin, we found that eribulin binds soluble tubulin at a single site; however
36 -ray crystallography, we first revealed that Eribulin binds to a site on beta-tubulin that is require
37           Overall, our results indicate that eribulin binds with high affinity to microtubule plus en
38 bservations that mitotic blockade induced by eribulin, but not ER-076349, is irreversible as measured
39 emonstrate that the microtubule destabilizer eribulin, but not the microtubule stabilizer paclitaxel,
40 work shows that the microtubule destabilizer eribulin, but not the microtubule stabilizer paclitaxel,
41 indings provide mechanistic insight into how eribulin can induce innate immune signaling independent
42  taxane- and anthracycline-exposed patients, Eribulin, CAPE, or carboplatin; and (3) for taxane-expos
43  to Dato-DXd (6 mg/kg every 3 weeks) or ICC (eribulin/capecitabine/vinorelbine/gemcitabine).
44 e tolerability and efficacy of a gemcitabine-eribulin combination in this population.
45 nce in OS in favor of patients randomized to eribulin compared with control in patients with bone, ly
46 group analysis of the efficacy and safety of eribulin compared with dacarbazine in patients with LPS,
47 urvival was improved in patients assigned to eribulin compared with those assigned to an active contr
48 gnificantly improved in patients assigned to eribulin compared with those assigned to dacarbazine (me
49 signed to an active control, suggesting that eribulin could be a treatment option for advanced soft-t
50                          Targeting EMT using eribulin could help improve OCS patient outcomes.
51                                              Eribulin demonstrated activity with manageable tolerabil
52 ibited anterograde axonal transport, whereas eribulin did not.
53                                              Eribulin does not suppress dynamic instability at microt
54                                              Eribulin (E7389), a mechanistically unique microtubule i
55                                              Eribulin (ERI), clinically utilized for locally advanced
56                            Notably, although eribulin exhibited greater DRG and SN penetration than p
57  B and other members of the halichondrin and eribulin families of compounds, this novel approach prov
58 y per investigator's choice of capecitabine, eribulin, gemcitabine, or vinorelbine (60% enrolment cap
59 eaths (10 [4%] vs 3 [1%]); one death (in the eribulin group) was considered treatment-related by the
60                A new convergent synthesis of eribulin has been achieved, using (1) catalytic asymmetr
61 s, ketone 4sc, containing all the carbons of Eribulin, has been synthesized from 1s and 3c.
62                         Finally, the highest eribulin IC(50) quartile (>1 nM) exhibited significantly
63 quartile of cell lines exhibiting the lowest eribulin IC(50) values was not enriched for specific his
64  2 study showed activity and tolerability of eribulin in advanced or metastatic soft-tissue sarcoma.
65 studies are justified to explore the role of eribulin in earlier lines of therapy as well as in combi
66 study evaluated efficacy and tolerability of eribulin in heavily pretreated patients with metastatic
67                                     Finally, eribulin increased expression of genes related to immune
68                 Interestingly, we found that Eribulin increases the frequency of EB3 comet "splitting
69                                              Eribulin inhibits this oligomer formation 4-6-fold, whil
70                   These results suggest that eribulin is a global inhibitor of tubulin polymer format
71          The nontaxane microtubule inhibitor eribulin is an approved therapeutic for metastatic breas
72 growth by 50%, we found that one molecule of eribulin is bound per two microtubules, indicating that
73                                              Eribulin is currently undergoing phase III clinical tria
74 mice exposed to the antitubulin cancer drugs eribulin, ixabepilone, paclitaxel, or vinorelbine at MTD
75 l, 145 mg/m2, every 21 days or chemotherapy (eribulin, ixabepilone, vinorelbine, gemcitabine, paclita
76 ts of this exploratory analysis suggest that eribulin may be efficacious for the treatment of locally
77 ving oncogenic mutations, we postulated that eribulin may exhibit properties of a precision oncology
78  significantly improved in women assigned to eribulin (median 13.1 months, 95% CI 11.8-14.3) compared
79 east cancer were randomly allocated (2:1) to eribulin mesilate (1.4 mg/m(2) administered intravenousl
80  randomly assigned (1:1) patients to receive eribulin mesilate (1.4 mg/m(2) intravenously on days 1 a
81                                              Eribulin mesilate is a non-taxane microtubule dynamics i
82 cline, were randomly assigned 1:1 to receive eribulin mesylate (1.4 mg/m(2) intravenously on days 1 a
83  with an anthracycline and a taxane received eribulin mesylate (1.4 mg/m(2)) as a 2- to 5-minute intr
84                                              Eribulin mesylate (E7389), a nontaxane microtubule dynam
85                                              Eribulin mesylate (E7389), a synthetic analogue of the m
86          Overall, our findings indicate that eribulin mesylate induces less neuropathy in mice than p
87                                 In contrast, eribulin mesylate produced no significant deleterious ef
88                                              Eribulin mesylate, a novel microtubule-targeting analogu
89 e more severe neuropathy in mice relative to eribulin mesylate, paralleling their toxicity profiles i
90 of three drugs: paclitaxel, ixabepilone, and eribulin mesylate.
91 les, indicating that the binding of a single eribulin molecule at a microtubule end can potently inhi
92 ral information, we engineered a fluorescent Eribulin molecule.
93                   We demonstrate that single Eribulin molecules specifically interact with microtubul
94                              Vinorelbine and eribulin more effectively inhibited OCS growth than stan
95                          Median OS times for eribulin (n = 554) and capecitabine (n = 548) were 15.9
96 y 22, 2013, we randomly assigned patients to eribulin (n=228) or dacarbazine (n=224).
97 dverse event leading to discontinuation from eribulin, occurring in 24 (5%) of 503 patients.
98 penia (at day 15), an alternative regimen of eribulin on days 1 and 8 of a 21-day cycle was administe
99 omer formation or the inhibitory activity of eribulin on this process.
100 ed therapy were randomly assigned to receive eribulin or capecitabine as their first-, second-, or th
101 y TPC (21-day cycles of either capecitabine, eribulin or vinorelbine).
102  (n = 88) from a randomized phase 2 trial of eribulin pembrolizumab for patients with metastatic HR+
103 the binding of two halichondrin B analogues, eribulin (previously, ER-086526, E7389) and ER-076349, t
104  of eribulin studies (301 and 305) indicated eribulin prolonged overall survival (OS) in patients wit
105 tinum-based chemotherapy, and treatment with eribulin reduced mesenchymal characteristics and N-MYC e
106                                              Eribulin represents an important treatment option for pa
107                     Our results suggest that eribulin's in vivo superiority derives from its ability
108 butes to long-term cell-viability loss after eribulin's irreversible blockade.
109 revealed a greater than 15,000-fold range in eribulin sensitivity (IC(50) = 0.005-89 nM) among the ce
110 2A, STK11, and KEAP1 was not associated with eribulin sensitivity.
111                                              Eribulin showed a significant and clinically meaningful
112               Camrelizumab plus apatinib and eribulin shows promising efficacy with a measurable safe
113                                              Eribulin strongly inhibits formation of the 1:2 stathmin
114                     Prior pooled analysis of eribulin studies (301 and 305) indicated eribulin prolon
115                                              Eribulin targets microtubules, suppressing dynamic insta
116 ived molecules, such as the chemotherapeutic eribulin, the calcium-channel blocker manoalide, and ant
117 ted in ligated sciatic nerves of control and eribulin-treated mice, but not in paclitaxel-treated mic
118                                  Gemcitabine-eribulin treatment response and survival for cisplatin-i
119                                              Eribulin treatment resulted in an accumulation of intrac
120 patients with liver metastases randomized to eribulin versus control (median: 13.4 versus 11.3 months
121 val of heavily pretreated patients receiving eribulin versus currently available treatments.
122                   PFS was also improved with eribulin versus dacarbazine (2.9 v 1.7 months, respectiv
123 , 0.51; 95% CI, 0.35 to 0.75; P < .001) with eribulin versus dacarbazine, respectively.
124 ble after 3-6 months after administration of eribulin, vinorelbine, and ixabepilone, we observed dela
125 mpared with physician's choice chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) in
126 gent chemotherapy of the physician's choice (eribulin, vinorelbine, capecitabine, or gemcitabine) in
127 ceive sacituzumab govitecan or chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine).
128  and 8, every 21 days) or TPC (capecitabine, eribulin, vinorelbine, or gemcitabine) until disease pro
129 ion In patients with previously treated LPS, eribulin was associated with significantly superior OS a
130      Activation of the cGAS-STING pathway by eribulin was further found to be mediated by the accumul
131                     In this phase III study, eribulin was not shown to be superior to capecitabine wi
132                               Longer OS with eribulin was observed in all LPS histologic subtypes and
133                                              Eribulin was previously tested in unselected patients wi
134                                  Using [(3)H]eribulin, we found that eribulin binds soluble tubulin a
135                   Focusing on paclitaxel and eribulin, we performed a 2-week MTD-dosing regimen, foll
136  with fluorouracil, taxanes, platinum and/or eribulin, whereas the de novo mutational signature I ide
137 cy of microtubule-targeting drugs, including eribulin, which has previously been shown to reverse EMT
138     This phase III randomized trial compared eribulin with capecitabine in patients with locally adva
139          Purpose A phase III study comparing eribulin with dacarbazine in patients with advanced lipo
140  metastatic soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine

 
Page Top